NIHSS Score Interpretation
| NIHSS Score | Severity | Interpretation | Clinical Guidance |
|---|---|---|---|
| 0 | No Stroke Symptoms | No detectable neurological deficit on 15-item exam | Does not exclude stroke — posterior circulation and lacunar infarcts can score 0. Urgent MRI DWI if symptoms present. |
| 1–4 | Minor | Minimal deficit; patient likely able to walk and communicate | Consider IV tPA if deficit is disabling (isolated aphasia, hemianopia); thrombectomy generally not indicated unless large vessel occlusion on CTA. Close monitoring for early deterioration. |
| 5–15 | Moderate | Significant neurological deficit; may impair ambulation and ADLs | IV tPA within window (3–4.5 hrs); CTA head/neck for LVO assessment. Thrombectomy candidacy if LVO identified and ASPECTS ≥ 6. Stroke unit admission. |
| 16–20 | Moderate to Severe | Large cortical or multi-territory deficit; significant disability expected | Emergent CTA for LVO. Strong thrombectomy candidacy if LVO present and within extended window. IV tPA bridge if eligible. ICU or stroke unit. Neurosurgery consult for hemorrhagic transformation risk. |
| 21–42 | Severe | Major hemispheric or brainstem stroke; altered consciousness likely | Emergent thrombectomy for LVO regardless of IV tPA eligibility. Airway management. Consider malignant MCA infarct protocol (decompressive hemicraniectomy criteria). Family counseling re: prognosis. |
About the NIH Stroke Scale
The NIH Stroke Scale (NIHSS) was developed by Thomas Brott and colleagues at the University of Cincinnati and National Institutes of Health and published in Stroke in 1989. It was designed to provide a standardized, reproducible, and rapid quantitative measure of neurological deficit in acute ischemic stroke — enabling consistent communication among clinicians, objective monitoring of stroke progression and response to treatment, and valid enrollment criteria for clinical trials.
Since its validation in the NINDS tPA trial (1995) — which demonstrated that IV alteplase improved outcomes in patients with ischemic stroke at 3 months — the NIHSS has been embedded in the eligibility criteria, outcome definitions, and treatment algorithms of virtually every acute stroke intervention. It is now mandated in Joint Commission-certified Primary and Comprehensive Stroke Centers.
The 11 NIHSS Domains
Items 1a–1c: Level of Consciousness
LOC items assess the reticular activating system and its cortical projections. Item 1a scores arousal (0=alert, 3=unresponsive); Items 1b and 1c test specific cognitive responses to verbal commands. These early items catch large hemispheric strokes and posterior fossa events with brainstem involvement. Notably, 1b instructions specify that the examiner scores the first answer only — repeated attempts after self-correction do not improve the score.
Item 2: Best Gaze
Horizontal gaze testing identifies frontal eye field or brainstem pathways involvement. A "forced deviation" toward one side (score 2) indicates a large frontal lobe lesion driving gaze toward the lesion side, or a pontine lesion driving gaze away. Internuclear ophthalmoplegia (INO) is typically scored as 1. Only horizontal gaze is tested; vertical gaze palsy, nystagmus, and monocular changes are not captured.
Item 3: Visual Fields
Confrontation testing using finger-counting or visual threat detects hemianopia from occipital cortex or optic tract lesions. Monocular visual loss is scored as 1 if due to retinal infarction (central retinal artery occlusion). Bilateral hemianopia (cortical blindness) scores 3 — these patients may be unaware of their visual loss (Anton syndrome).
Item 4: Facial Palsy
Lower motor neuron (Bell's palsy) vs. upper motor neuron (stroke) distinction matters here: central facial palsy (stroke) spares the forehead due to bilateral cortical innervation. Score 1–3 for central UMN palsy. Complete ipsilateral facial paralysis including forehead suggests peripheral (LMN) etiology — not typical stroke, score carefully.
Items 5–6: Motor Arm and Leg (Bilateral)
Each limb is scored independently (0–4). Arms are tested at 90° (sitting) or 45° (supine) for 10 seconds; legs at 30° supine for 5 seconds. Score 4 (no movement) is distinguished from score 3 (some movement but cannot overcome gravity). Amputees or prior pre-existing deficits: score as 9 (untestable) and document. Maximum motor contribution to NIHSS = 16 (4 limbs × 4 points).
Item 7: Limb Ataxia
Tests cerebellar function via finger-nose-finger (upper) and heel-to-shin (lower). Ataxia is scored only when clearly disproportionate to weakness. If the patient cannot move the limb at all (score 3–4 on motor), ataxia = 0 (untestable, score 0). Ataxia in stroke typically indicates ipsilateral cerebellar hemisphere or contralateral cerebellar pathways involvement.
Item 8: Sensory
Pinprick sensation tested in all extremities and face. Hemibody sensory loss (including face) = 1; bilateral or complete loss = 2. Obtunded patients can be tested by grimace to noxious stimulus. Pure sensory stroke (lacunar) from thalamic or thalamocortical tract infarcts can score 1–2 with otherwise minimal NIHSS — clinically disabling despite low total score.
Item 9: Best Language (Aphasia)
Assessed via picture description, object naming (pictured items), and reading standard sentences. Global aphasia (score 3) means no usable expressive or receptive language. Broca's (expressive) aphasia typically scores 1–2; Wernicke's (receptive) aphasia tends to score higher due to comprehension failure affecting multiple items. Aphasia is the most prognostically significant language impairment — even mild aphasia (score 1) significantly impairs quality of life.
Items 10–11: Dysarthria and Neglect
Dysarthria is motor speech production (articulation) separate from aphasia (language). A patient can be dysarthric without aphasia (cerebellar or bulbar dysarthria) or aphasic without dysarthria. Extinction/inattention (item 11) captures hemispatial neglect — the patient may have intact sensation but extinguishes one side when both are stimulated simultaneously. Right MCA strokes produce neglect far more frequently than left (typically producing aphasia instead).
NIHSS in tPA and Thrombectomy Decisions
The 1995 NINDS tPA trial established IV alteplase benefit for ischemic stroke within 3 hours regardless of stroke severity, but excluded patients with rapidly improving or very minor stroke (NIHSS 0–1). Current AHA/ASA guidelines (2019) allow tPA for minor but disabling deficits (e.g., isolated aphasia NIHSS 2). The upper NIHSS limit (previously 25) is no longer an absolute contraindication. For mechanical thrombectomy, landmark trials (MR CLEAN, SWIFT PRIME, DAWN, DEFUSE 3) demonstrated benefit across a wide NIHSS range (typically 6–30) when LVO is confirmed by CTA/MRA and tissue viability criteria are met.
Limitations of the NIHSS
- Anterior circulation bias: NIHSS is heavily weighted toward large MCA territory strokes; posterior circulation deficits (diplopia, dysphagia, ataxia, isolated field cuts) are incompletely captured — a major basilar artery occlusion can score < 10
- Intubation and sedation: Pharmacological sedation and neuromuscular blockade invalidate multiple items; document as untestable
- Training dependence: Reliable scoring requires NIHSS certification (free at strokeassociation.org) — interrater reliability improves substantially with training
- Right hemisphere stroke underscoring: Neglect (item 11) partially captures right hemisphere deficits, but executive dysfunction, visuospatial impairment, and anosognosia are poorly measured
- Aphasia scoring inconsistency: Language items (1b, 1c, 9) can compound scoring complexity in multilingual or pre-existing aphasic patients
- Not a prognostic tool in isolation: Outcome depends on infarct location and volume, collateral flow, time to treatment, age, comorbidities, and reperfusion success — NIHSS alone is insufficient
References
Brott T, Adams HP Jr, Olinger CP, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20(7):864–870.
The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1587.
Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines. Stroke. 2019;50(12):e344–e418.
Lyden P, Brott T, Tilley B, et al. Improved reliability of the NIH Stroke Scale using video training. Stroke. 1994;25(11):2220–2226.